What is the treatment for a urinary tract infection (UTI) caused by Aerococcus fecalis in a urine analysis (UA) specimen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Aerococcus urinae UTI

For a urine specimen growing Aerococcus urinae, treat with ampicillin or amoxicillin as first-line therapy, or nitrofurantoin for uncomplicated cystitis, with treatment duration of 7-14 days based on infection severity. 1, 2, 3

Organism Recognition and Clinical Context

  • Aerococcus urinae is an emerging uropathogen primarily affecting elderly patients with multimorbidity, chronic urinary retention, or indwelling catheters 1, 3
  • This organism has historically been misidentified as streptococci, leading to underrecognition, but modern MALDI-TOF mass spectrometry has improved detection 3
  • While most infections are mild UTIs, serious complications including urosepsis and infective endocarditis can occur, particularly in older males with underlying urinary tract conditions 1, 4, 3

First-Line Treatment Options

For uncomplicated cystitis:

  • Nitrofurantoin 100 mg orally every 6 hours for 7 days achieves clinical cure in 71% and microbiological cure in 76% of A. urinae UTI cases 2
  • Ampicillin or amoxicillin 500 mg orally every 8 hours for 7-14 days is highly effective, as A. urinae demonstrates 100% susceptibility to these agents 1, 5, 3

For complicated UTI or pyelonephritis:

  • Ampicillin remains the preferred agent given universal susceptibility 5, 3
  • Ciprofloxacin may be considered for pyelonephritis, though resistance rates of approximately 11% exist 2, 5

Alternative and Adjunctive Therapies

  • Pivmecillinam achieves success in A. urinae cystitis cases 2
  • Nitroxoline demonstrates high activity (MIC50/90 1/2 mg/L) and 97.6% of isolates would be susceptible using EUCAST breakpoints, though clinical validation is needed 5
  • Penicillin combined with an aminoglycoside shows synergy and is recommended for serious infections such as endocarditis or urosepsis 4, 3

Critical Treatment Considerations

  • Always obtain urine culture with antibiotic susceptibility testing before initiating therapy, as resistance patterns vary and prompt culture-specific treatment prevents clinical progression 1
  • A. urinae shows 100% susceptibility to benzylpenicillin, ampicillin, meropenem, rifampicin, nitrofurantoin, and vancomycin 5
  • Resistance to ciprofloxacin occurs in 10.9% of isolates, making fluoroquinolones less reliable empirically 5
  • A. urinae is resistant to sulphamethoxazole, and trimethoprim sensitivity testing has methodological problems, so avoid trimethoprim-sulfamethoxazole 3

Treatment Duration

  • For uncomplicated cystitis: 7 days is appropriate 2
  • For complicated UTI or when using parenteral therapy: extend to 14 days based on clinical response 6
  • For serious invasive infections (endocarditis, urosepsis): prolonged therapy with combination regimens is necessary 4

Common Pitfalls to Avoid

  • Do not dismiss A. urinae as a contaminant or misidentify it as Streptococcus species - this delays appropriate treatment 3
  • Avoid empiric fluoroquinolone monotherapy given the 11% resistance rate 5
  • Do not use trimethoprim-sulfamethoxazole, as A. urinae is inherently resistant to sulphamethoxazole 3
  • Recognize that elderly patients with multimorbidity are at highest risk for invasive disease requiring more aggressive management 1, 3

References

Research

Aerococcus: an increasingly acknowledged human pathogen.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2016

Research

Three cases of serious infection caused by Aerococcus urinae.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1999

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.